The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries
vaccines. Chapter 8 presents further discussion of the grouping of vaccine candidates.
COMPARISON OF COSTS ASSOCIATED WITH DISEASES
Another way to compare candidates for accelerated vaccine development would be to compare the extent to which they would render unnecessary expenditures for treating diseases or avert other disease-related economic losses, for example, lost work productivity, and their cost-effectiveness in doing so. To make such comparisons it is necessary to know (or to obtain reliable estimates on) the costs associated with each disease. The costs incurred in vaccine development and in vaccination programs are discussed in Chapters 5 and 7, respectively.
TABLE 4.8 The Median Infant Mortality Equivalence Values for Respondents from the United States
Infant Mortality Equivalents
Under 5 Years
60 Years and Over
Moderate localized pain and/or mild systemic reaction, or impairment requiring minor change in normal activities, and associated with some restriction of work activity
Moderate pain and/or moderate impairment requiring moderate change in normal activities, e.g., housebound or in bed, and associated with temporary loss of ability to work
Severe pain, severe short-term impairment, or hospitalization
Mild chronic disability (not requiring hospitalization, institutionalization, or other major limitation of normal activity, and resulting in minor limitation of ability to work)
Moderate to severe chronic disability (requiring hospitalization, special care, or other major limitation of normal activity, and seriously restricting ability to work)